510(k) device
NeuroStar
Neuronetics, Inc. · Transcranial Magnetic Stimulator (OBP, Class II) · First FDA decision Aug 24, 2022, newest Aug 24, 2022DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
37
Naming "NeuroStar"
MAUDE reports
220
Brand "NeuroStar", since 2015
PubMed studies
27
Mentioning "NeuroStar"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NeuroStar
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K222230 · Decided Aug 24, 2022 · 30 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "NeuroStar", any status and sponsor, newest update first.
- Effects of rTMS on Cognitive Functions and Behavior in Individuals With Autism Spectrum DisorderRecruiting
King Saud UniversityAcademic, hospital or other
NCT06524310 · 80 participants (planned) · Start Jul 20, 2024 · Primary completion Apr 30, 2028
Device: Stimulation with low frequency rTMS at 1 Hz · For: Autism Spectrum Disorder
Sites: Riyadh, Saudi Arabia
- Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal DepressionActive, not recruiting
Rana JawishAcademic, hospital or other
NCT07928908 · 100 participants (planned) · Start Sep 23, 2026 · Primary completion Sep 2028
Device: Transcranial Magnetic Stimulation (TMS) · For: Perinatal Depression
Sites: Salt Lake City, Utah
- Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and AnxietyCompleted
Northwestern UniversityAcademic, hospital or other
NCT01701284 · 24 participants · Start Dec 2012 · Primary completion May 2023
Device: Repetitive Transcranial Magnetic Stimulation (rTMS) · For: Cancer in Remission (Any Type or Stage); Depression; Anxiety
Sites: Chicago, Illinois
34 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NeuroStar", and for the whole product code for context.
This brand
220 reports: 4 malfunction, 213 injury, 1 death
Whole product code OBP
337 reports: 9 malfunction, 323 injury, 2 death
Newest reports for this brand
- NeuroStar TMS SystemOther
MW6003698 · Received Oct 8, 2026 · Event dated Sep 1, 2026
Device type: Transcranial Magnetic Stimulator (OBP)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Memory Loss/Impairment; Irritability; Sleep Dysfunction; Cognitive Changes
3004824012-2026-00024 · Received Oct 2, 2026 · Event dated Aug 26, 2026
Device type: Transcranial Magnetic Stimulator (OBP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Convulsion/Seizure
3004824012-2026-00022 · Received Sep 28, 2026 · Event dated Aug 28, 2026
Device type: Transcranial Magnetic Stimulation System For Obsessive-Compulsive Disorder (QCI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Convulsion/Seizure
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NeuroStar"[tiab]. The summary above synthesizes these.
- A new aspiration device equipped with a hydro-separator for acute ischemic stroke due to challenging soft and stiff clots.
Kaneko N, Ghovvati M, Komuro Y, et al. · Interv Neuroradiol · 2022
- Patient- and Technician-Oriented Attitudes Toward Transcranial Magnetic Stimulation Devices.
Lonergan B, Nguyen E, Lembo C, et al. · J Neuropsychiatry Clin Neurosci · 2018
- A multisite observational real-world study on the effectiveness of repetitive transcranial magnetic stimulation therapy for patients with treatment-resistant depression in Japan.
Matsuda Y, Kito S, Hiraki F, et al. · Psychiatry Res · 2024Multicenter Study, Observational Study
- The Anxiolytic and Antidepressant Effects of Transcranial Magnetic Stimulation in Patients With Anxious Depression.
Hutton TM, Aaronson ST, Carpenter LL, et al. · J Clin Psychiatry · 2023Research Support, Non-U.S. Gov't
- Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
Croarkin PE, Elmaadawi AZ, Aaronson ST, et al. · Neuropsychopharmacology · 2021Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression.
Horvath JC, Mathews J, Demitrack MA, et al. · J Vis Exp · 2010Research Support, Non-U.S. Gov't, Video-Audio Media
- Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder.
Carpenter L, Aaronson S, Hutton TM, et al. · Brain Stimul · 2021Research Support, Non-U.S. Gov't
- One hertz versus ten hertz repetitive TMS treatment of PTSD: A randomized clinical trial.
Kozel FA, Van Trees K, Larson V, et al. · Psychiatry Res · 2019Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation.
Sackeim HA, Aaronson ST, Carpenter LL, et al. · J Affect Disord · 2020Research Support, Non-U.S. Gov't
- Comparative Efficacy and Acceptability of 3 Repetitive Transcranial Magnetic Stimulation Devices for Depression: A Meta-Analysis of Randomized, Sham-Controlled Trials.
Matsuda Y, Yamazaki R, Kishi T, et al. · Neuropsychobiology · 2022Network Meta-Analysis
- Time to remission analysis for major depressive disorder after repetitive transcranial magnetic stimulation (rTMS).
Manzardo AM, Ely B, Davila MC · Ment Illn · 2019
- Transcranial magnetic stimulation for major depressive disorder: a pragmatic approach to implementing TMS in a clinical practice.
Derstine T, Lanocha K, Wahlstrom C, et al. · Ann Clin Psychiatry · 2010Case Reports, Review
Other devices of this type
Also filed under product code OBP.
- NeuroStar TMS Therapy SystemNeuronetics, Inc. · 510(k) 2022
- BrainsWay Deep TMS SystemBrainsway , Ltd. · 510(k) 2025
- Apollo TMS Therapy SystemMag & More GmbH · 510(k) 2026
- MagVita TMS Therapy w/MagPro R20Tonica Elektronik A/S · 510(k) 2017
- NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 510(k) 2024
- Magstim Horizon 3.0 TMS Therapy SystemMagstim Company, Ltd. · 510(k) 2023
- HORIZON TMS Therapy System with NavigationMagstim Company, Ltd. · 510(k) 2019
- Nexstim Navigated Brain Stimulation (NBS) 6 System (NBS6)Nexstim Oyj · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.